Cardiovascular effects of endocannabinoids - The plot thickens

Prostaglandins and Other Lipid Mediators

Volumn 61, Issue 1-2, 2000, Pages 71-84

  Kunos, George ^a   Járai, Zoltán ^a   Varga, Károly ^a   Liu, Jie ^a   Wang, Lei ^a   Wagner, Jens A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 Arachidonoyl glycerol; Anandamide; Blood pressure; Vasodilation

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CANNABINOID; CANNABINOID RECEPTOR; DEXANABINOL; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; RIMONABANT; TETRAHYDROCANNABINOL;

BLOOD VESSEL TONE; BRADYCARDIA; CARDIOVASCULAR EFFECT; HUMAN; HYPOTENSION; IN VITRO STUDY; KNOCKOUT MOUSE; NONHUMAN; REVIEW; SPINAL ANIMAL; VAS DEFERENS;

EID: 0343570142     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(00)00056-3     Document Type: Article

References (81)

1. Devane W.A., Dysarz F.A., Johnson L.S., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 34:1988;605-613.
2. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
3. Shire D., Carillon C., Kaghad M., et al. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem. 270:1995;3726-3731.
4. Gerard C.M., Mollereau C., Vassart G., Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in the testis. Biochem J. 279:1991;129-134.
5. Munro S., Thomas K.L., Abu-Shaar. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
6. Matsuda L.A. Molecular aspects of cannabinoid receptors. Crit Rev Neurobil. 11:1997;143-166.
7. Rinaldi-Carmona M., Barth F., Héaulme M., et al. SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
8. Rinaldi-Carmona M., Barth F., Millan J., et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther. 284:1998;644-650.
9. Ledent C., Valverde O., Cossu G., et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 283:1999;401-404.
10. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA. 96:1999;5780-5785.
11. Buckley NE, McCoy KL, Mezey E, et al. Eur J Pharmacol, submitted.
12. Devane W.A., Hanuš L., Breuer A., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
13. Mechoulam R., Ben-Shabat S., Hanuš L., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 50:1995;83-90.
14. Sugiura T., Kondo S., Sukagawa A., et al. 2-Arachidonoylglycerol a possible endogenous cannabinoid receptor ligand in brain . Biochem Biophys Res Commun. 215:1995;89-97.
15. Vogel Z., Barg J., Levy R., Saya D., Heldman E., Mechoulam R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem. 61:1993;352-355.
16. Felder C.C., Briley E.M., Axelrod J., Simpson J.T., Mackie K., Devane W.A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned cannabinoid receptor and stimulates receptor mediated signal transduction. Proc Natl Acad Sci USA. 90:1993;7656-7660.
17. Bisogno T., Maurelli S., Melck D., De Petrocellis L., Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem. 272:1997;3315-3323.
18. Deutsch D.G., Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol. 46:1993;791-796.
19. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., Piomelli D. Functional role of high affinity anandamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
20. Hillard CJ. Biochemistry and pharmacology of the endocannabinoids anandamide and 2-arachidonoyl glycerol. Prostaglandins Lipid Med In press.
21. Di Marzo V., Fontana A., Cadas H., et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
22. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 288:1997;773-778.
23. Bisogno T., Sepe N., Melck D., Maurelli S., De Petrocellis L., Di Marzo V. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J. 322:1997;671-677.
24. 9-THC (cannabis) on cardiac performance with or without beta blockade. Circulation. 53:1976;703-709.
25. Benowitz N.L., Jones R.T. Cardiovascular effects of prolonged δ-9-tetrahydro-cannabinol ingestion. Clin Pharmacol Ther. 18:1975;287-297.
26. Rosenkrantz H. Cannabis, marijuana and cannabinoid toxicological manifestations in man and animals. In: O'Brien K, Kalant H, editors. Cannabis and health hazards. Addiction Research Foundation, Toronto. pp. 91-175.
27. 9-trans-tetrahydrocannabinol. J Pharm Pharmacol. 26:1974;186-192.
28. Wagner J.A., Varga K., Kunos G. Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med. 76:1998;824-836.
29. Varga K., Lake K., Martin B.R., Kunos G. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol. 278:1995;279-283.
30. Siqueira S.W., Lapa A.J., Riberio do Valle J. The triple effect induced by delta 9-tetrahydrocannabinol on the rat blood pressure. Eur J Pharmacol. 58:1979;351-357.
31. Abadji V., Lin S., Taha G., et al. (R)-Methanadamide a chiral novel anandamide possessing higher potency and metabolic stability . J Med Chem. 37:1994;1889-1893.
32. Lake K.D., Compton D.R., Varga K., Martin B.R., Kunos G. Cannabinoid-induced hypotension and bradycardia in rats is mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther. 281:1997;1030-1037.
33. Járai Z., Wagner J.A., Varga K., et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site of action distinct from CB1 and CB2 receptors. Proc Natl Acad Sci USA. 96:1999;14136-14141.
34. Lake K.D., Martin B.R., Kunos G., Varga K. Cardiovascular effects of anandamide in anaesthetized and conscious normotensive and hypertensive rats. Hypertension. 29:1997;1204-1210.
35. Stein E.A., Fuller S.A., Edgemond W.S., Campbell W.B. Physiological and behavioral effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. Br J Pharmacol. 199:1996;107-114.
36. Varga K., Lake K.D., Huangfu D., Guyenet P.G., Kunos G. Mechanism of the hypotensive action of anandamide in anaesthetized rats. Hypertension. 28:1996;682-686.
37. Pertwee R., Griffin G., Hanuš L., Mechoulam R. Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. Eur J Pharmacol. 259:1994;115-120.
38. Ishac E.J.N., Jiang L., Lake K.D., Varga K., Abood M., Kunos G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol. 118:1996;2023-2028.
39. Malinowska B., Godlewski G., Bucher B., Schlicker E. Cannabinoid CB1 receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat. Naunyn Schmiedeberg's Arch Pharmacol. 356:1997;197-202.
40. Niederhoffer N., Szabo B. Effect of the cannabinoid receptor agonist WIN 55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol. 126:1999;457-466.
41. Vidrio H., Sanchez-Salvatori M.A., Medina M. Cardiovascular effects of (-)-11-OH-δ-8-tetrahydrocannabinol-dimethylheptyl in rats. J Cardiovasc Pharmacol. 28:1996;332-336.
42. Wagner JA, Járai Z, Kunos G. Effects of cannabinoids on systemic hemodynamics and organ blood flows in the rat: coronary and cerebral vasodilation mediated by CB1 receptors. Submitted.
43. Varga K., Wagner J.A., Bridgen D.T., Kunos G. Platelet- and macrophage-derived cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 12:1998;1035-1044.
44. Mechoulam R., Fride E., Ben-Shabat S., Meiri U., Horowitz M. Carbachol, an acethylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur J Pharmacol. 362:1998;R1-R3.
45. Sugiura T., Kodaka T., Nakane S., et al. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. J Biol Chem. 274:1999;2794-2801.
46. Járai Z, Wagner JA, Goparaju SK, et al. Cardiovascular effects of 2-arachidonoyl glycerol in anaesthetized mice. Hypertension 2000;35:679-84.
47. Goparaju S.K., Ueda N., Taniguchi K., Yamamoto S. Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem Pharmacol. 57:1999;417-423.
48. Di Marzo V., Bisogno T., De Petrocellis L., et al. Biosynthesis and inactivation of endocannabinoid 2-arachidonylglycerol in circulating and tumoral macrophages. Eur J Biochem. 264:1999;258-267.
49. Bolton T.B., Lang R.J., Takewaki T. Mechanisms of action of noradrenaline and carbachol on smooth muscle of guinea-pig anterior mesenteric artery. J Physiol. 351:1984;549-572.
50. Bauersachs J., Popp R., Hecker M., Sauer E., Fleming I., Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation. 94:1996;3341-3347.
51. McCulloch A.I., Bottrill F.E., Randall M.D., Hiley C.R. Characterization of EDHF-mediated relaxations in the rat isolated superior arterial bed. Br J Pharmacol. 120:1997;1431-1438.
52. Campbell W.B., Gebremedhin D., Pratt P.F., Harder D.R. Identification of eicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 78:1996;415-423.
53. Fisslthaler B., Popp R., Kiss L., et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature. 401:1999;493-497.
54. + is an endothelium-derived hyperpolarizing factor in rat arteries. Nature. 396:1998;269-272.
55. Randall M.D., Alexander S.P., Bennett T., et al. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Commun. 229:1996;114-120.
56. Randall M.D., Kendall D.A. Endocannabinoids a new class of vasoactive substances . Trends Pharmacol Sci. 19:1998;55-58.
57. Wagner J.A., Varga K., Járai Z., Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension. 33:(Part II):1999;429-434.
58. White R., Hiley C.R. A comparison of EDHF-mediated and anandamide induced relaxations in the rat isolated mesenteric artery. Br J Pharmacol. 122:1997;1573-1584.
59. Zygmunt P.M., Högestätt E.D., Waldeck K., Edwards G., Kirkup A.J., Weston A.H. Studies on the effects of anandamide in rat hepatic artery. Br J Pharmacol. 122:1997;1679-1686.
60. Plane F., Holland M., Waldron G.J., Garland C.J., Boyle J.P. Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries. Br J Pharmacol. 121:1997;1509-1511.
61. Pratt P.F., Hillard C.J., Edgemont W.S., Cambell W.B. N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am J Physiol. 274:1998;H375-H381.
62. Chataigneau T., Félétou M., Thollon C., et al. Cannabinoid CB1 receptor and endothelium-dependent hyperpolarization in guinea-pig carotid, rat mesenteric and porcine coronary arteries. Br J Pharmacol. 123:1998;968-974.
63. White R., Hiley C.R. The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br J Pharmacol. 125:1998;689-696.
64. Chaytor A.T., Martin P.E.M., Evans W.H., Randall M.D., Griffith T.M. The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol. 520:1999;539-550.
65. 2+ channel current. Am J Physiol. 266:1999;H2085-H2093.
66. Sugiura T., Kodaka T., Nakane S., Kishimoto S., Kondo S., Waku K. Detection of an endogenous cannabinoid molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun. 243:1998;838-843.
67. Liu J, Gao B, Mirshahi F, Sanyal A, Khanolkar R, Makriyannis A, Kunos G. Functional CB1 cannabinoid receptors in vascular endothelial cells. Biochem J In press.
68. Deutsch D.G., Goligorsky M.S., Schmid P.C., et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest. 100:1997;1538-1546.
69. Di Marzo V., Bisogno T., Melck D., et al. Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett. 436:1998;449-454.
70. Zygmunt P.M., Petersson J., Andersson D.A., et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 400:1999;452-457.
71. 2+-induced relaxation of isolated arteries. Hypertension. 30:1997;1431-1439.
72. 2+-induced relaxation. J Pharmacol Exp Ther. 289:1999;245-250.
73. Zygmunt P.M., Högestätt E.D. Role of potassium channels in endothelium-dependent relaxation resistant to nitroarginine in the rat hepatic artery. Br J Pharmacol. 117:1996;1600-1606.
74. 2+ in endothelial cells. Br J Pharmacol. 126:1999;1593-1600.
75. Fimiani C., Mattocks D., Cavani F., et al. Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells coupling to nitric oxide release . Cell Signal. 11:1999;189-193.
76. Fleming I., Schermer B., Popp R., Busse R. Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists. Br J Pharmacol. 126:1999;949-960.
77. Mechoulam R, Breuer A, Hanus L, et al. HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA, In press.
78. 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA. 95:1998;8268-8273.
79. Wagner J.A., Varga K., Ellis E.F., Rzigalinski B.A., Martin B.R., Kunos G. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature. 390:1997;518-521.
80. Calignano A., La Rana G., Beltramo M., Makriyannis A., Piomelli D. Potentiation of anandamide hypotension by the transport inhibitor AM404. Eur J Pharmacol. 337:1997;R1-R2.
81. Di Marzo V., De Petrocellis L., Sepe N., Buono A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J. 316:1996;977-984.